Trial Profile
Autologous T Cells With a Chimeric Antigen Receptor in Patients With CD19-positive Malignant B Cell Leukemia and Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Nov 2021
Price :
$35
*
At a glance
- Drugs CAR-T cell therapies (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell leukaemia; Lymphoma
- Focus Adverse reactions
- 17 Jun 2018 Status changed from not yet recruiting to recruiting according to the results presented at the 23rd Congress of the European Haematology Association.
- 17 Jun 2018 Preliminary results presented at the 23rd Congress of the European Haematology Association.
- 19 Oct 2016 New trial record